nAMD and DME Management: Rapid Response From ARVO

Real-world outcomes with anti-vascular endothelial growth factor (VEGF) therapies in the management of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) are often not comparable to those of clinical studies. Discrepancies in these outcomes have been associated with undertreatment due to high treatment burden and the associated loss of patient adherence to dosing schedules. Newer therapies with novel mechanisms that extend intervals between dosing schedules, along with personalized treatment protocols utilizing FDA approved therapies, have sought to address treatment burden while still providing visual acuity gains. In this CE activity, experts in the field review and discuss the latest clinical studies regarding therapies that provide durable improvements to visual and anatomic outcomes, and evaluate evidence-based and real-world studies demonstrating their application in the treatment of patients with nAMD and DME.